Omeros Corp (NASDAQ: OMER)

Omeros Corporation, a clinical-stage biopharmaceutical company listed on the NASDAQ Global Market under the symbol OMER, is dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. Headquartered in Seattle, Washington, the company operates in the biopharmaceutical industry, focusing on immunologic diseases and complement-mediated disorders.

Omeros' primary business activities revolve around developing therapeutics that target the complement system, a crucial component of the immune system. The company's development programs are centered on diseases and disorders associated with the complement system, specifically the lectin and alternative pathways. Omeros' lead candidate in its lectin pathway program is narsoplimab (OMS721), a human monoclonal antibody targeting MASP-2, which is in clinical development for various indications, including TA-TMA, severe COVID-19, PASC, and IgA nephropathy. Additionally, Omeros has developed an assay platform to identify hyperactivation of the lectin pathway, which is linked with COVID-19-related ARDS and may be involved in the pathogenesis of other ARDS forms and PASC.

The MASP-3 program at Omeros is focused on developing inhibitors of MASP-3, the key activator of the alternative pathway of complement. OMS906, a human monoclonal antibody targeting MASP-3, is the lead candidate in this program, with clinical development rapidly advancing toward Phase 3 clinical trials in multiple alternative pathway-related disorders, such as PNH and C3G.

Omeros also boasts a diverse group of preclinical programs, including immuno-oncology platforms aimed at developing novel adoptive T cell/CAR-T therapies, immunomodulators, immunotoxins, and cancer vaccines. The company's PDE7 inhibitor program, which includes OMS527, is focused on creating therapeutics for treating addictions, compulsive disorders, and movement disorders.

In the complement-targeted therapeutic space, Omeros competes with Alexion Pharmaceuticals, Inc. and Biogen Inc., both of which have developed and commercialized products targeting the complement system. However, Omeros' focus on the lectin and alternative pathways of complement and its proprietary antibody and small-molecule inhibitors set it apart from its competitors, providing a unique opportunity to develop novel therapeutics for a range of diseases and disorders.

Omeros' customers are likely to include hospitals, clinics, and other healthcare organizations, as its products are intended for use by patients and healthcare providers. The company's product portfolio includes narsoplimab (OMS721), OMS906, and various preclinical programs, such as immuno-oncology platforms and the PDE7 inhibitor program.